Essais liés8clinical trials
VilleLeedslocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT02861014

Ouvrir le site du centre

Essais cliniques associés

8
MoléculeIndication / populationPhaseNCTTitreStatut
Cladribine (MAVENCLAD®) SEP Phase 2/3 NCT04695080 ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT02861014 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) COMPLETED
DYNE-251 Myopathies Phase 1/2 NCT05524883 DELIVER — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping ACTIVE_NOT_RECRUITING
Histotripsie — HistoSonics Edison System Cancer Non applicable NCT05432232 CAIN — The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy COMPLETED
Histotripsie — HistoSonics Edison System Cancer Non applicable NCT04573881 The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK) ACTIVE_NOT_RECRUITING
XEN1101 Épilepsie Phase 3 NCT05718817 X-TOLE4 — An Open-label Study of XEN1101 in Epilepsy ENROLLING_BY_INVITATION
APL-130277 Parkinson Phase 3 NCT02542696 Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease COMPLETED
Sacituzumab govitecan-hziy Cancer Phase 3 NCT06486441 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) ACTIVE_NOT_RECRUITING